Advanced Solid Cancers Clinical Trial
Official title:
A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers
The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in participants with cancers that have failed to respond to T cell checkpoint inhibiting antibodies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02792465 -
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00886782 -
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03512340 -
Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
|
Phase 1 | |
| Terminated |
NCT03254732 -
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
|
Phase 1 | |
| Terminated |
NCT00337376 -
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
|
Phase 1 | |
| Completed |
NCT00478101 -
Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain
|
Phase 2 | |
| Completed |
NCT01019941 -
Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer
|
Phase 1 | |
| Completed |
NCT02694822 -
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
|
Phase 1/Phase 2 |